Latest Strategy Changes News

InFocus Group Holdings has launched Codexa, a proprietary sweepstakes casino platform targeting the US market, and secured an expanded contract for its Prodigy9 subsidiary in Thailand, while navigating cash flow pressures amid ongoing R&D investment.

Scalare Partners (ASX:SCP) reported a striking 771% year-on-year revenue increase to $5.26 million in Q3 FY26, alongside positive operating cashflow of $2.84 million, driven by ecosystem growth and new partnerships.

Venari Minerals has delivered a maiden JORC Inferred Mineral Resource Estimate for its Red Mountain Lithium Project in Nevada, revealing 3.03 million tonnes of contained Lithium Carbonate Equivalent. The company also reported improved beneficiation results and completed a share buyback to streamline its register.

Hamelin Gold is gearing up for a busy 2026 with planned drilling across three key Western Australian gold provinces, underpinned by a solid cash position and strategic asset sales.

Cooper Metals has completed all regulatory approvals for a ~1,400m RC drill program at Ardmore North, targeting Q2 2026 commencement. The company also executed a strategic asset swap to acquire the Pyramid Gold Project, backed by a nearly $1 million placement.

Fat Prophets Global Contrarian Fund (ASX: FPC) is raising up to $8.45 million through a pro-rata rights issue priced at a premium, offering one option per new share. The issue is partly underwritten and sees directors committing to full participation.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Stakk Ltd (ASX: SKK) has delivered a striking 272% jump in gross receipts to $5.36 million in Q3 FY26, reversing prior cash outflows with a positive net cash flow of $2.25 million and closing the quarter with $17.34 million in cash.

Nexion Group plans to delist from the ASX in April 2026 after disposing of its main assets, appointing Robert Minson as CEO to spearhead software acquisitions aimed at rebuilding the company for re-admission.

Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.

Ionic Rare Earths (ASX: IXR) has secured a £12 million UK government grant offer for its Belfast rare earth magnet recycling facility and is progressing its Brazilian JV and Ugandan heavy rare earths project, reinforcing its role in ex-China supply chains.

Energy Resources of Australia (ERA) advances rehabilitation at its Ranger site while awaiting a Federal Court decision on Rio Tinto’s compulsory acquisition bid. Seasonal conditions and higher rainfall have delayed critical Pit 3 capping trials, with financial reserves remaining strong despite no production activity.